Day One Biopharmaceuticals, Inc. (DAWN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Brisbane, CA, United States. The current CEO is Jeremy Bender.
DAWN has IPO date of 2021-05-27, 181 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $2.22B.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
